Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences Inc is advancing innovative therapeutic programs that target hepatitis B virus (HBV) infection and dysbiotic microbiomes, which positions the company well within the biotechnology sector. The firm is generating substantial revenue primarily from its HBV cure program, which includes promising drug candidates that demonstrate robust antiviral activity and the potential for peak sales of nearly $4 billion in the U.S. Moreover, recent clinical results and ongoing financial support, including a $175 million equity financing, indicate a strong likelihood of continued success and viability through at least 2027.

Bears say

Assembly Biosciences Inc continues to experience negative financial sentiment due to its long-standing history of operating losses and lack of established profitability. There are significant concerns surrounding the efficacy and safety of its drug candidates, particularly regarding potential negative outcomes for the ABI-6250 and ABI-1179/5366 programs, which may hinder advancement in clinical stages. Additionally, low virologic response rates, coupled with observations of adverse safety signals, contribute to a dim outlook for the company’s future revenue generation, primarily reliant on the success of its HBV-cure program.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.